27 Sep, EOD - Indian

SENSEX 85571.85 (-0.31)

Nifty 50 26178.95 (-0.14)

Nifty Bank 53834.3 (-1.00)

Nifty IT 42312.6 (0.36)

Nifty Midcap 100 60381.15 (-0.15)

Nifty Next 50 77813.25 (0.94)

Nifty Pharma 23519.1 (1.15)

Nifty Smallcap 100 19242 (-0.10)

27 Sep, EOD - Global

NIKKEI 225 39829.56 (2.32)

HANG SENG 20632.3 (3.56)

S&P 5759.51 (0.16)

Login/Signup
LOGIN HERE
Cancel

Mankind Pharma Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 543904 | NSE Symbol : MANKIND | ISIN : INE634S01028 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
17-Sep-2024 20-Sep-2024 Raising funds through Debt Instr. Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/09/2024 inter alia to consider and approve the raising of funds by way of issue of non-convertible debentures commercial papers other debt securities or any other security or any combination thereof for an amount as may be decided by the Board. Outcome of Board Meeting held today i.e. September 20, 2024 Raising of funds and issuance of corporate guarantee (As Per BSE Announcement dated on 20.09.2024)
18-Jul-2024 31-Jul-2024 Quarterly Results Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of Board of Directors of the Company will be held on Wednesday July 31 2024 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30 2024. Further in continuation of our earlier letter dated June 26 2024 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till August 2 2024. The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. Outcome of Board Meeting- Financial Results for the quarter ended June 30, 2024. (As Per BSE Announcement dated on 31.07.2024)
08-May-2024 15-May-2024 Accounts Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2024 inter alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31 2024 and to evaluate various options or proposals for raising funds through any of the permissible modes subject to the receipt of necessary approvals. The Board of Directors of the Company at its meeting held today i.e. May 15 2024, has inter alia consider and approve the: 8. Re-appointment of M/s M. K. Kulshrestha & Associates, Cost Accountants as the Cost Auditors of the Company for the Financial Year 2024-25. 9. Re-appointment of M/s Dayal & Maur, Company Secretaries as the Secretarial Auditors of the Company for the Financial Year 2024-25. Raising of Funds by issuance of such number of Equity Shares having face value of Re. 1 each of the Company (Equity Shares) and/or other eligible securities or any combination thereof, or an aggregate amount not exceeding Rs. 7,500 Crore or an equivalent amount thereof by way of issuance of Equity/Equity linked securities under Qualified Institutional Placement or through issuance of FCCBs, ADRs/ GDRs/ Debt Securities or through any permissible mode. The Board of Directors of the Company at its meeting held today i.e. May 15, 2024 has inter alia consider and approved the increase in Authorized Share Capital of the Company. Outcome of Board Meeting held today i.e. May 15, 2024 Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). (As Per BSE Announcement Dated on 15/05/2024)
02-Apr-2024 02-Apr-2024 Subsidiary Company The Board of Directors of the Company at its meeting held today i.e. April 2, 2024, has inter-alia, considered and approved the following: 1. Slump sale of the Over the Counter ('OTC') . The Board of Directors of the Company at its meeting held today i.e. April 2, 2024 has inter-alia, considered and approved the Incorporation of a wholly owned subsidiary by the name Mankind Consumer Products Private Limited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs. Read less..
16-Jan-2024 31-Jan-2024 Quarterly Results Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday January 31 2024 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended on December 31 2023. Further in continuation of our earlier letter dated December 27 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till February 02 2024. The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. Outcome of Board Meeting held today i.e. January 31, 2024 (As Per BSE Announcement dated on 31.01.2024)
11-Oct-2023 31-Oct-2023 Quarterly Results Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Tuesday October 31 2023 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30 2023. Further in continuation of our earlier letter dated September 27 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till November 02 2023. The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. Outcome of Board Meeting held today i.e. October 31, 2023 Announcement under Regulation 30 (LODR) - Amalgamation / Merger (As Per BSE Announcement dated on 31.10.2023) Newspaper Publication of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2023 (As Per BSE Announcement Dated on 01/11/2023) Submission of application for reclassification from Promoter & Promoter Group category to Public Category under Regulation 31A of the SEBI (LODR) Regulations, 2015 (As Per BSE Announcement Dated on 27/11/2023)
18-Jul-2023 02-Aug-2023 Quarterly Results Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday 2nd August 2023 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on 30th June 2023. Further in continuation of our earlier letter dated 29th June 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed upto 48 hours after the declaration of unaudited standalone and consolidated financial results of the Company for the quarter ended on 30th June 2023. Mankind Pharma Limited has informed BSE about Board Meeting to be held on 02 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Outcome of Board Meeting as per letter attached. The Board at its meeting held on 02nd August, 2023 has inter alia approved the following: 1. Re-appointment of Mr. Ramesh Juneja as Chairman and Whole Time Director. 2. Re-appointment of Mr. Rajeev Juneja as Vice Chairman and Managing Director. 3. Re-appointment of Mr. Sheetal Arora as Whole-time Director and Chief Executive Officer. 4. Re-designation of Mr. Suresh Raju Penmetsa as Chief Risk Officer and Vice President EHS. 5. Re-appointment of M/s Dayal & Maur, Company Secretaries as the Secretarial Auditor of the Company for the FY 2023-24. 6. Ratification of Mankind Employee Stock Option Plan 2022. 7. Ratification of grant of employee stock option to the employees of subsidiary company(ies)/Group Company/ Associate Companies. Item no. 1, 2, 3, 6 and 7 are subject to approval of the members of the Company. (As per BSE Announcement Dated on 02/08/2023)
22-May-2023 30-May-2023 Accounts Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on 30th May 2023 inter-alia to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023. Further in continuation of our earlier letter dated 9th May 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for dealing in the securities of the Company shall remain closed upto 48 hours after the declaration of the Financial Results of the Company for the quarter and financial year ended on 31st March 2023. We are enclosing herewith as follows: a. Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023; b. Auditors' report with unmodified opinion on the audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31st March 2023; and c. The declaration from Chief Financial Officer pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), 2015, Regulations confirming the unmodified opinion of the statutory auditors on the audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31st March 2023. The meeting of Board of Directors of the Company commenced at 05:05 p.m. (IST) and concluded at 06:45 p.m. The above mentioned documents will also be available on the website of the Company at www.mankindpharma.com. 1. The Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023 2. Re-Appointment of M/s. M.K. Kulshrestha & Associates, Cost Accountants as the Cost Auditors of the Company for the Financial Year 2023-24 3. Appointment of Mr. Anil Gupta, Associate Vice President & Head - Internal Audit as the Internal Auditor of the Company with effect from Financial Year 2023-24 in place of retiring Internal Auditor M/s Ghosh Khanna & Co. LLP, Chartered Accountants The disclosure with respect to the point no. 1 already has been submitted to the Stock Exchange through letter dated 30th May 2023 under Subject 'Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023'. The meeting of Board of Directors of the Company commenced at 05:05 p.m. (IST) and concluded at 06:45 p.m. (IST). (As Per BSE Announcement dated on 30.05.2023)